Survival in Pulmonary Arterial Hypertension: a Reappraisal of the NIH Risk Stratification Equation

Overview

Journal Eur Respir J

Specialty Pulmonary Medicine

Date 2009 Dec 25

PMID 20032020

Citations 193

Authors

T Thenappan

S J Shah

S Rich

L Tian

S L Archer

M Gomberg-Maitland

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to determine contemporary survival in pulmonary arterial hypertension (PAH), and to investigate whether or not the National Institutes of Health (NIH) equation remains an accurate predictor of survival. In 576 patients with PAH referred during 1991-2007, observed survival was described using the Kaplan-Meier method. In patients with idiopathic, familial and anorexigen-associated PAH (n = 247), observed versus NIH equation predicted survival was compared. A new survival prediction equation was developed using exponential regression analysis. The observed 1-, 3- and 5-yr survival in the total cohort were 86, 69 and 61%, respectively. In patients with idiopathic, familial and anorexigen-associated PAH, the observed 1-, 3- and 5-yr survival (92, 75 and 66%, respectively) were significantly higher than the predicted survival (65, 43 and 32%, respectively). The new equation (P(t) = e(-A(x,y,z)t), where P(t) is probability of survival, t the time interval in years, A(x,y,z) = e((-1.270-0.0148x+0.0402y-0.361z)), x the mean pulmonary artery pressure, y the mean right atrial pressure and z the cardiac index) performed well when applied to published contemporary studies of survival in PAH. Contemporary survival in the PAH cohort was better than that predicted by the NIH registry equation. The NIH equation underestimated survival in idiopathic, familial and anorexigen-associated PAH. Once prospectively validated, the new equation may be used to determine prognosis.

Citing Articles

Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox.

Pulido T, de la Cruz-Perez S, Valencia D, Conde R, Lescano A, Zayas N Int J Cardiol Congenit Heart Dis. 2025; 19:100573.

PMID: 40066342 PMC: 11891735. DOI: 10.1016/j.ijcchd.2025.100573.

Impact of BMPR2 mutation on the severity of pulmonary arterial hypertension: a systematic review and meta-analysis.

Wu J, Huang Q, Zhang Y, De Z, Fu H, Zhan Y Respir Res. 2025; 26(1):74.

PMID: 40022182 PMC: 11871596. DOI: 10.1186/s12931-025-03145-5.

Beyond Tumors: The Pivotal Role of TRIM Proteins in Chronic Non-Tumor Lung Diseases.

Huang X, Yu W, Wei A, Wang X, Chen S J Inflamm Res. 2025; 18:1899-1910.

PMID: 39935527 PMC: 11812559. DOI: 10.2147/JIR.S499029.

Risk stratification and treatment goals in pulmonary arterial hypertension.

Dardi F, Boucly A, Benza R, Frantz R, Mercurio V, Olschewski H Eur Respir J. 2024; 64(4).

PMID: 39209472 PMC: 11525341. DOI: 10.1183/13993003.01323-2024.

The prognostic value of right ventricular outflow tract velocity time integral in patients with pulmonary hypertension.

Colak A, Kumral Z, Sezgin D, Omeroglu Simsek G, Demirci Yildirim T, Kis M ESC Heart Fail. 2024; 11(5):3332-3340.

PMID: 38961603 PMC: 11424340. DOI: 10.1002/ehf2.14934.

References

Thenappan T, Shah S, Rich S, Gomberg-Maitland M . A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J. 2007; 30(6):1103-10. DOI: 10.1183/09031936.00042107. View

Sitbon O, Humbert M, Jais X, Ioos V, Hamid A, Provencher S . Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005; 111(23):3105-11. DOI: 10.1161/CIRCULATIONAHA.104.488486. View

Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G . Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006; 27(5):589-95. DOI: 10.1093/eurheartj/ehi728. View

McLaughlin V, Shillington A, Rich S . Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002; 106(12):1477-82. DOI: 10.1161/01.cir.0000029100.82385.58. View

McLaughlin V . Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest. 2006; 36 Suppl 3:10-5. DOI: 10.1111/j.1365-2362.2006.01688.x. View

Macchia A, Marchioli R, Marfisi R, Scarano M, Levantesi G, Tavazzi L . A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J. 2007; 153(6):1037-47. DOI: 10.1016/j.ahj.2007.02.037. View

McLaughlin V, Sitbon O, Badesch D, Barst R, Black C, Galie N . Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005; 25(2):244-9. DOI: 10.1183/09031936.05.00054804. View

DAlonzo G, Barst R, Ayres S, Bergofsky E, Brundage B, Detre K . Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115(5):343-9. DOI: 10.7326/0003-4819-115-5-343. View

Badesch D, Abman S, Simonneau G, Rubin L, McLaughlin V . Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007; 131(6):1917-28. DOI: 10.1378/chest.06-2674. View

10.

Gomberg-Maitland M, Huo D, Benza R, McLaughlin V, Tapson V, Barst R . Creation of a model comparing 6-minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension. J Heart Lung Transplant. 2007; 26(7):732-8. DOI: 10.1016/j.healun.2007.04.013. View

11.

Sandoval J, Bauerle O, Palomar A, Gomez A, Beltran M, Guerrero M . Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation. 1994; 89(4):1733-44. DOI: 10.1161/01.cir.89.4.1733. View

12.

Barst R, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C . Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006; 28(6):1195-203. DOI: 10.1183/09031936.06.00044406. View

13.

Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P . Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002; 40(4):780-8. DOI: 10.1016/s0735-1097(02)02012-0. View

14.

Farber H, Loscalzo J . Pulmonary arterial hypertension. N Engl J Med. 2004; 351(16):1655-65. DOI: 10.1056/NEJMra035488. View

15.

McGoon M, Gutterman D, Steen V, Barst R, McCrory D, Fortin T . Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004; 126(1 Suppl):14S-34S. DOI: 10.1378/chest.126.1_suppl.14S. View

16.

Nootens M, Schrader B, Kaufmann E, Vestal R, Long W, Rich S . Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest. 1995; 107(1):54-7. DOI: 10.1378/chest.107.1.54. View

17.

Patterson J, Naughton J, Pietras R, GUNNAR R . Treadmill exercise in assessment of the functional capacity of patients with cardiac disease. Am J Cardiol. 1972; 30(7):757-62. DOI: 10.1016/0002-9149(72)90151-8. View

18.

Fisher M, Mathai S, Champion H, Girgis R, Housten-Harris T, Hummers L . Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 2006; 54(9):3043-50. DOI: 10.1002/art.22069. View

19.

Shah S, Thenappan T, Rich S, Sur J, Archer S, Gomberg-Maitland M . Value of exercise treadmill testing in the risk stratification of patients with pulmonary hypertension. Circ Heart Fail. 2009; 2(4):278-86. DOI: 10.1161/CIRCHEARTFAILURE.108.807826. View

20.

Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani M, Branzi A . A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009; 30(4):394-403. PMC: 2642921. DOI: 10.1093/eurheartj/ehp022. View